Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
- Conditions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02706899
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02702141
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT02614794
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Paris Regional Medical Center / US Oncology, Paris, Texas, United States
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02614560
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02594163
- Locations
- 🇺🇸
Good Samaritan Hospital, Torrance, California, United States
🇺🇸Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02592876
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT02572167
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02552121
- Locations
- 🇧🇪
CHU de Liège, Liege, Liège, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇭🇺Semmelweis Egyetem Onkológiai Központ, Budapest, Hungary
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
- Conditions
- Interventions
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02533570
- Locations
- 🇺🇸
Clayton Medical Associates, P.C., Saint Louis, Missouri, United States
🇺🇸TriWest Research Associates, LLC, El Cajon, California, United States
🇺🇸Lakes Research, LLC, Miami Lakes, Florida, United States
Safety Study of SEA-CD40 in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT02376699
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States